University of California, Irvine
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, Irvine sits in the top decile of US sponsors by registered trial count (#96 of 15,742 sponsors by registered trial count).
University of California, Irvine: 368 sponsored US clinical trials, 74 recruiting.
University of California, Irvine sponsors 368 registered US clinical trials on ClinicalTrials.gov, 74 of them currently recruiting, and 228 completed. 27 of these trials are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 6 trials.
Top-decile sponsor footprint
University of California, Irvine ranks in the top decile of sponsors by registered trial count (#96 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
228 of 258 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
368 total, page 1 of 8
Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
NCT07693452
ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
NCT06824363
Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
NCT07628634
Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study
NCT07581080
PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)
NCT07549958
Resilience in Reentry: Cognitive-Behavioral Resilience Training for Parolees With Adjustment Challenges
NCT07167719
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
NCT07447050
HOPE Intervention for Fitness
NCT07114822
Telemedicine to Support Living Kidney Donor Candidates
NCT07206069
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
NCT07281781
Mapping Ibogaine Neural Dynamics in Opioid Use Disorder
NCT07226570
Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy
NCT07073807
Wearable Device and Behavioral Support for Enhancing Arm Use After Stroke
NCT07042152
EndoPAT Device for Endothelial Dysfunction in ED
NCT06720597
Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
NCT05733689
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
NCT07062172
Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Formers
NCT06335537
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
NCT07064018
The THRIVE Study: Teaching Healthy Regulation in Individuals & Vulnerable Environments
NCT06821035
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
NCT06853158
Conscious Pregnancy: Supporting Maternal Cardiometabolic Health With Mindfulness
NCT06898658
Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
NCT06783751
Analgesic Response to Opioids in Patients With Fibromyalgia After Conventional Acupuncture Versus Sham Acupuncture
NCT06571110
My Life and My Experiences Project
NCT06821178
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
NCT06771544
Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
NCT06693323
The Effects of Energy Healing in Fibromyalgia
NCT06552728
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
NCT06580002
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
NCT06682728
PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis
NCT06511037
The Effects of Core Shamanism in Fibromyalgia
NCT06579261
Impact of Intraoperative ICG on Functional Outc in RARP
NCT06446648
CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT
NCT06453460
A Biobehavioral Intervention for Latino/Hispanic Young Adults with Cancer
NCT06338475
Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
NCT06112353
mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer
NCT06335667
Effect of Fasting on Patient Outcomes After Wide-Awake, Local Anesthesia-only, No Tourniquet (WALANT) Procedures
NCT05819801
Positive Affect Treatment for Adolescents with Early Life Adversity
NCT06273137
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
NCT06221800
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
NCT06229860
Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
NCT06002607
A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors
NCT05836688
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
NCT06028828
Pharmacotherapy in Conjunction With Lifestyle Counseling for Management of Weight Regain After Bariatric Surgery
NCT05975580
Latinx Children and Surgery
NCT06020677
Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis
NCT05844865
Vaginal Changes After CO2 Laser
NCT06691178
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
NCT05586776
Acupuncture Therapy and Hypertension
NCT05530512
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
NCT05600842
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 46 |
| Phase 2 | 46 |
| Phase 3 | 6 |
| Phase 4 | 21 |
Therapeutic Areas
What is open in the University of California, Irvine pipeline
74 recruiting of 368 indexed (20% open); 228 completed (62%).
Phase mix: 27 late (III/IV) vs 92 early (I/II) (early-phase heavy).
Top condition: Cancer (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, Irvine: open-pipeline peers nationwide
Peers matched on 368 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of California, Irvine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 368 trials (± recruiting share)
- Northwell Health · 370 trials · 22% recruiting
- UNC Lineberger Comprehensive Cancer Center · 366 trials · 22% recruiting
- Roswell Park Cancer Institute · 365 trials · 16% recruiting
- New York State Psychiatric Institute · 364 trials · 3% recruiting
Sponsors near 20% open enrollment (± trial volume)
- University of Miami · 20% recruiting · 721 trials
- Endeavor Health · 20% recruiting · 94 trials
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
Related
What to do with this University of California, Irvine page
368 registered trials is a research-attention snapshot, not an endorsement of University of California, Irvine or any single study.
- 74 of University of California, Irvine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cancer is the condition University of California, Irvine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of California, Irvine pipeline card: 368 registered trials from official public datasets.Report a data error.